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Short Title: Pregnancy in mixed connective tissue disease 
Key words: mixed connective tissue disease, anti -U1RNP, pregnancy, pregnancy complications, autoimmune 
disease, congenital heart block, neonatal lupus, antibodies  
Key Messages 
1. In our multicentre cohort, women with mixed connective tissue disease(MCTD)  had a live-birth-rate of 72%. 
2.Pregnancy counseling should be considered in women withanti-U1RNP positivity.   
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Abstract  
Objectives 
In this study, we aimed to investigate fetal and maternal pregnancy outcomes from a large 
multicentre cohort of women diagnosed with Mixed Connective Tissue Disease(MCTD) and 
the presence of anti-U1RNP antibodies. 
Methods 
This multicentre retrospective cohort study describes the outcomes of 203 pregnancies in 94 
consecutive women ever pregnant who fulfilled the established criteria of MCTD with 
confirmed U1RNP positivity.  
Results  
The fetal outcomes in 203 pregnancies were as follows: 146(71.9%) live births, 38(18.7%) 
miscarriages (first trimester pregnancy loss of <12 weeks ’ gestation), 18(8.9%) stillbirths 
(pregnancy loss after 20 weeks’ gestation), 11(5.4%) cases showed intrauterine growth 
restriction (IUGR). Maternal pregnancy outcomes were as follows: eight(3.9%) cases 
developed pre-eclampsia, two(0.9%) cases developed eclampsia, 31(15.3%) women 
developed gestational hypertension and three(1.5%) developed gestational 
diabetes. Women with MCTD and antiphospholipid antibodies and pulmonary or muscular 
involvement had worse fetal outcomes compared to those without.  
Moreover, we report a case of complete CHB (0.45%) and a case of cutaneous NL, both born 
to a mother with positive isolated anti-U1RNP and negative anti-Ro/SSA antibodies. 
Conclusion 
In our multicentre cohort, women with MCTD had a live-birth-rate of 72%. While the true 
frequency of heart block associated with anti-U1RNP remains to be determined, this study 
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might raise the consideration of echocardiographic surveillance in this setting. Pregnancy 
counselling should be considered in women with MCTD.   
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1.0 Introduction 
Mixed connective tissue disease (MCTD) is classified by the presence high titers of antibodies 
to U1-ribonucleoprotein (RNP) in patients with ‘puffy hands’, Raynaud’s phenomenon, 
arthritis and myositis[1–3]. Testing for extractable nuclear antibodies (ENA) is mandatory to 
classify patients suspected with connective tissue diseases (CTD).  
In patients with any known CTD, specific situations such as the planning of a pregnancy, 
requires ENA profiling as the presence of maternal anti-Ro/SSA is strongly associated with 
the development of neonatal cutaneous lupus and fetal complete congenital heart block 
(CHB)[4].   
However, little is known about the maternal and fetal pregnancy outcomes in women with 
anti-U1RNP. A recent interesting observation was a case of CHB in a fetus born to a mother 
with MCTD with isolated high titre anti-U1RNP, who was persistently negative for anti-
Ro/SSA and anti-La/SSB[5]. The autopsy report of the child, who died 28 days post-partum 
due to several complications, confirmed loss and calcification of the myocytes in the bundle 
of His extending into the Purkinje fibres’ with AV node sparring[5].  While the histopathology 
of this anti-U1RNP associated case of heart block did not reveal the characteristic fibrosis of 
the AV node, a similar result has been reported for two post-natal deaths associated with 
autoimmune CHB[6]. 
Herein, we report pregnancy outcomes from a large multicentre cohort of anti-U1RNP 
positive women and present the results of a systematic review of the literature.  
2.0 Methods 
This multicentre retrospective cohort study describes the fetal and maternal outcomes of 
203 pregnancies in 94 women ever pregnant, who attended the S. Giovanni Bosco Hospital 
and Sant’ Anna University Hospital, Turin, Italy, the Lupus Unit, Department of 
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Rheumatology at St Thomas’ Hospital, London, UK, Hospital das Clínicas da Faculdade de 
Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil, Hospital Reina Sofia de Córdoba, 
Spain, ASST SpedaliCivili di Brescia, Brescia, Italy. 
Data collection was performed retrospectively from patient notes, pregnancies occurred in 
the time range 2000 – 2017. Autoantibody detection and laboratory profile  were measured 
before conception, as per standard care of all centers of the study. 
Inclusion criteria: Women ever been pregnant who fulfilled the established criteria of MCTD 
with confirmed anti-U1RNP positivity [1,3,7].  
2.1 Statistics: 
Categorical variables are presented as number (%) and continuous variables are presented 
as mean (S.D.). The significance of baseline differences was determined by the chi -squared 
test, Fisher’s exact test or the unpaired t-test, as appropriate. A two-sided P-value <0.05 was 
statistically significant. All statistical analyses were performed using SPSS version 19.0 (IBM, 
Armonk, NY, USA).  
2.2 Systematic review:  
A structured search for publications on Neonatal Lupus (NL) with anti-U1RNP antibodies 
positive patients in the absence of anti-Ro/SSA was undertaken in PubMed using the 
following search criteria: ("ribonucleoproteins"[MeSHTerms] OR 
"ribonucleoproteins"[AllFields] OR "ribonucleoprotein"[AllFields]) AND 
("antibodies"[MeSHTerms] OR "antibodies"[AllFields]) AND ("infant, newborn"[MeSHTerms] 
OR ("infant"[AllFields] AND "newborn"[AllFields]) OR "newborninfant"[AllFields] OR 
"neonatal"[AllFields]). Two-hundred-seventy-six publications were identified and six 
additional studies were found. Two-hundred-sixty studies were excluded and a total of 22 
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studies were identified for detailed evaluation by two reviewers (MR and KS). Disagreements 
were resolved by consensus; if consensus could not be achieved, a third party (SS) would 
provide an assessment of eligibility. As the data on eligibility were dichotomous (eligible: 
yes/no), inter rater agreement at both the title and abstract review stage and the full article 
review stage was determined by calculation of Cohen’s kappa coefficient (k=0.92). Fourteen 
studies were included [5,8–20], the search strategy is presented in Figure 1.  
3.0 Results:  
3.1 Systematic Review 
Fourteen studies, including a total of 17 patients with NL born to women carrying positive 
anti-U1RNP antibodies in the absence of anti-Ro/SSA,  were retrieved from the literature 
search(5.8–20). Table 1 illustrates the main findings of the studies included in the analysis.  
Briefly, 16 (94.1%) patients presented with skin involvement, two patients (11.7%) with 
heart involvement (two cases of congenital atrioventricular heart block) and seven patients 
(41.1%) with potentially related systemic involvement in addition to the characteristic skin 
rash (two cases of thrombocytosis, two cases of thrombocytopenia, one case of anaemia, 
one case of hypotonia and one case of hepatomegaly).  The maternal diagnosis was SLE in 
seven cases, MCTD in ten cases and in one case the diagnosis was not specified.  
3.2 Patients characteristics of our multicentre cohort 
The analysis included 94 consecutive women (mean age at conception 28.9 years, S.D. 6.3; 
mean age at data collection 45.1 years old, S.D. 10.9; mean disease duration at data 
collection 12.9 years, S.D. 8.5) who had a total of 203 pregnancies.  
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All patients were diagnosed with MCTD according to the established criteria  [1,2,21]. 
Thirteen patients tested positive for aPL and, of those, 6 patients also fulfilled the 
classification criteria for antiphospholipid syndrome (APS) (two women had a previous 
history of thrombosis and four patients had a previous history of pregnancy morbidity)[22]. 
Demographic, clinical and laboratory characteristics are summarized in Table 2.  
Thirty-two (15.8%) patients received low-dose aspirin (LDA) and fifteen (7.4%) cases were 
treated with low molecular weight heparin (LMWH) during pregnancy. Thirty-three patients 
received steroid treatment during pregnancy [median daily dosage 5 mg (range 3.6-40 mg)]. 
Immunosuppressant treatment with Azathioprine or Cyclosporine-A was given in eleven 
(5.4%) and two (0.9%) women, respectively. Treatment received by the patients before, 
during and after pregnancy are outlined in Table 3.  
Of the 203 pregnancies analysed the fetal outcomes were as follows: 147 (72.4%) resulted in 
live births, 38 (18.7%) in miscarriages defined as pregnancy loss of less than 12 weeks 
gestation, 18 (8.9%) in stillbirths (pregnancy loss after 20 weeks gestation)and eleven(5.4%) 
cases showed intrauterine growth restriction (IUGR). Maternal pregnancy outcomes were as 
follows: eight (3.9%) cases developed pre-eclampsia, two (0.9%) cases developed eclampsia, 
31 (15.3%) women developed gestational hypertension and three (1.5%) cases were 
diagnosed with gestational diabetes. When considering the live birth outcomes (147 live 
births), birth weight was <2500g in 23.6% and <1500g in 5.6%; in 15.7% of cases birth weight 
was below the 10th percentiles, while 3.4%  cases had a birth weight between the 10th and 
5th percentile, and 12.4% were under the 5th percentile. When considering gestational length 
in live births (total 147), 15.5% of all gestations lasted<37 weeks, 9.2% between 37 and 34 
weeks, and 6.4% under 34 weeks. The characteristics of fetal and maternal pregnancy 
outcomes are summarized in Table 4.  
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Patients with first trimester miscarriages when compared to those without, were 
significantly less frequently treated with HCQ (before [13% v.s. 42%; p< 0.05], during [13% 
v.s. 42%; p<0.05] and after [13% v.s. 56%;p< 0.001] pregnancy), low dose aspirin (LDA) 
(before [0% v.s. 21%; p< 0.001], during [0% v.s. 33%; p< 0.001] and after [0% v.s. 25%; p< 
0.001]  pregnancy), steroids (before [13% v.s. 40%; p< 0.05], during [7% v.s. 36%; p< 0.05] 
and after [0% v.s. 31%; p< 0.001] pregnancy) and azathioprine (AZA) (during [0% v.s. 13%; p< 
0.05]). 
When comparing patients who experienced still births compared to those without stillbirths, 
the former had a significantly higher frequency of clinical CTD manifestations, such as joints 
involvement (100% v.s. 69%; p< 0.05), muscular involvement (64% v.s. 31%; p< 0.05), 
pulmonary involvement (64% v.s. 27%; p< 0.05). The patients who experienced stillbirths 
had also a higher frequency of concomitant diagnosis of obstetric APS (11% v.s. 1%; p< 0.05) 
and had a lower rate of renal manifestations (0% v.s. 12%; p< 0.05).  
When comparing patients who experienced either miscarriages or stillbirths with patients 
who did not experience stillbirths, those with fetal death were more likely to have a 
concomitant diagnosis of obstetric APS (11% v.s. 0%; p< 0.05), muscular involvement (58% 
v.s. 25%; p< 0.05), pulmonary involvement (50% v.s. 23%; p< 0.05). The patients who did not 
experience either miscarriages or stillbirths had a higher frequency of previous treatment 
with LDA (before pregnancy [4% v.s. 22%; p< 0.05], during pregnancy [9% v.s. 34%; p< 
0.05]),treatment with HCQ (before [21% v.s. 45%; p< 0.05] and during [27% v.s. 57%; p< 
0.05] pregnancy) and treatment with AZA (during [0% v.s. 16%; p< 0.05]). 
3.3 Congenital Atrioventricular Heart Block- Case Presentation 
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A 33-year-old woman from China with no known previous medical history of connective 
tissue disease was referred to one of our tertiary pregnancy clinic for evaluation and follow-
up at 28 weeks’ gestation after detection of a decreased fetal heart rate upon routine 
obstetric ultrasonographic examination. Fetal echocardiography revealed a structurally 
normal heart with a ventricular rate of 50 to 55 beats/min, an atrial rate of 130 to 140 
beats/min, and no pericardial effusion. These findings were compatible with CHB. No extra-
cardiac abnormalities were detected at ultrasonographic examination. No infectious 
pathology, such as parvovirus B19, cytomegalovirus and Epstein-Barr virus, was found.  
The female baby, born via caesarean section at 38 weeks of gestation, weighed 2.855 g and 
was 49 cm in length. After delivery, her heart rate was 70 to 110 beats/min. 
Electrocardiography revealed complete AV block, with an atrial rate of 140 beats/min and a 
ventricular rate of 40 to 50 beats/min. Holter monitoring confirmed the complete AV block, 
and the baby required a pacemaker implantation.  
Results of laboratory examination of the baby showed that the haemoglobin level was 14.9 
g/dL, and the blood results were negative for anti-nuclear antibodies, anti-double stranded 
DNA (dsDNA), anti-La/SSB and anti-Ro/SSA antibodies. She tested positive only for anti-
U1RNP antibodies (81 UI/mL, cut-off of positivity >5 UI/mL).  
There were no skin lesions, no increase in hepatic transaminase levels and no 
thrombocytopenia. Echocardiographic evaluation showed normal left ventricular systolic 
and diastolic function. 
The mother's blood samples were negative for anti-La/SSB and anti-dsDNA and anti-Ro/SSA 
but were positive for anti-U1RNP antibodies. Her previous medical history, physical 
examination and serological profile were unremarkable. There was no previous pregnancy 
morbidity.  
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The blood sample was blindly tested in an external laboratory as previously described[23] 
(see supplementary material)and tested negative for anti-Ro60 native, anti-La recombinant, 
Ro52 recombinant, anti-Sm and confirmed the positive result for anti-U1RNP antibodies 
only.  
Due to anti-U1RNP antibodies positivity, she had been attending the Rheumatology 
outpatient clinic for a regular clinical and laboratory follow-up, during which she started to 
complain about worsening arthralgia and fatigue. About 24 months after her first pregnancy, 
she presented with puffy hands’, and arthritis on MCP joints, and complained about a ne w 
onset of Raynaud’s phenomenon. These findings were compatible with a diagnosis of MCTD 
and she was started on low-dose of prednisone. During her second pregnancy, obstetric 
ultrasonographic examinations and fetal echocardiography performed throughout 
pregnancy revealed a structurally normal fetal heart with a physiologic ventricular rate. The 
baby girl, born via caesarean section, weighed 2873 g and was 52 cm in length. After 
delivery, the neonate’s heart rate was  normal with no sign of CHB. However, the neonate, at 
birth, presented with annular erythematosus plaques with a slight scale, which appeared 
predominately on the scalp, neck, and on the trunk, suggestive of NL. Lesions resolved in a 
few weeks without scarring and without any specific treatment. 
4.0 Discussion: 
To the best of our knowledge, this is the first multicentre cohort study to describe the 
overall fetal and maternal pregnancy outcomes in MCTD women with positive anti-U1RNP 
antibodies. Moreover, we report the second case of complete CHB in a fetus born to a 
mother with isolated positive anti-U1RNP in the absence of Ro/SSA antibodies.  
Performing a systematic review of the literature of NL in patients with anti-U1RNP  in the 
absence of anti-Ro/SSA is confined to eighteen cases in total since 1987 (including our 
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reported case)[5,8–19]. Notably, only one case of CHB has previously been reported[5] 
(Table 4).  
Findings of fetal outcomes in our cohort suggest that the live-birth-rate was 71.9%, that 
18.7% ended in a first trimester pregnancy loss, 5.4% cases had IUGR and 8.9% of 
pregnancies ended in a stillbirth. Maternal pregnancy outcomes showed that 3.9% 
developed pre-eclampsia, 0.9% developed eclampsia, 15.3% of the mothers developed 
gestational hypertension and 1.5% were diagnosed with gestational diabetes. Of those 
patients who developed gestational diabetes, only one of the three was treated with 
steroids during pregnancy.  
Much focus has been on fetal and maternal pregnancy outcomes in women with SLE, who 
until four decades ago were advised against pregnancy due to a high rate of pregnancy 
morbidity including pregnancy losses, preterm birth and stillbirth[24]. Depending on the 
studies SLE cohort live birth rates are described as high as 90%, with 30% of miscarriages and 
preterm delivery rate of 30%. Women are now advised to be in remission prior to 
conception[25] and the identification of those women with a history of lupus nephritis[26–
28] or persistent aPL[27] as risk factors for adverse pregnancy outcomes allow for individual 
close monitoring. 
The pregnancy morbidity in women with SLE has improved over the last five decades from 
40% to less than 15% in recent years[29].  The European League against Rheumatism 
(EULAR) has very recently published their first clinical recommendations for the 
management of women with SLE and aPL during pregnancy, which is an important step of 
the international community and aims to provide a uniform approach for the treatment and 
surveillance of these high risk patients[30]. 
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As CTD’s in general have a female preponderance[31–34] and a proportion of CTD’s mostly 
affecting women of childbearing age[31,33,34], it is pertinent to address their effects on 
pregnancy outcomes. How come that pregnancy in MCTD has received very little 
attention[35,36]?  
Population based Norwegian data suggest a prevalence of MCTD of 3.8/100.000 with an 
incidence of 2.1/million/year and a female:male ratio as high as 3:1[33,34]. As a comparison 
the incidence of SLE in the UK according to the Clinical Practice Research Datalink (CPRD) is 
8.3/100,000/ year (for females) in the UK(4). The highest incidence rates of MCTD are 
described in those of African-Caribbean descent, 31.4/100,000/year compared to 
6.7/100,000/year for those of white European descent. Overall, the incidence rate for SLE is 
slightly higher than for MCTD, which may explain that little attention so far has been paid 
towards pregnancy complications in women with MCTD.  
Our results show a relatively high rate of fetal and maternal complications associated in 
women with MCTD with anti-U1RNP. In more detail, over 10% of the women in our cohort 
had cardiac involvement and almost one third of the patients had pulmonary involvement. 
Maternal cardiac involvement was not associated with increased adverse fetal outcomes. 
Due to a high maternal mortality, women with established cardiac involvement and/or 
pulmonary hypertension are advised against pregnancy [37]. It might well be that the high 
rate of pregnancy morbidity in our cohort reflects selection bias in a potentially general 
sicker MCTD population recruited from our tertiary centres only. 
Further, the rate of NL and complete CHB in our cohort is not negligible, being 2/203(1%) 
and 1/203 (0.5%) pregnancies, respectively. Complete CHB is a rare complication, which 
when associated with anti-SSA/Ro is most often detected between 18 and 25 weeks of 
gestation. Complete block (third degree) in the absence of any extra nodal disease is not 
 
14 
 
reversible and evidence does not support efficacy in the use of fluorinated corticosteroids 
[38]. In regards to treatments options to improve pregnancy outcomes in women with 
MCTD, very little is known at this stage. 
On the one hand, in a recent study, Sonesson and colleagues[39] suggested that echographic 
CHB surveillance still allows detection of fetuses with AVB II-III shortly after its development, 
allowing for timely treatment initiation and potentially better outcome. On the other hand, 
Evers et al. [40] suggest that a cost-effective strategy should be considered, focusing the 
fetal surveillance efforts on targeted screening strategies, such as using maternal antibody 
levels as a cost-effective alternative strategy. Notably, a recent paper by Cuneo and 
colleagues [41]supports that daily ambulatory fetal heart rate and rhythm monitoring done 
by the mother may identify blocks during a stage of transition from normal sinus rhythm to 
second degree block that may be reversible with anti-inflammatory therapy.  Importantly 
this home monitoring was very reassuring it that no mother missed heart block, i.e. there 
were no false negative results. In our study, the use of azathioprine and steroids was found 
to be associated with better pregnancy outcomes. Albeit randomized control trials will be 
needed to specifically investigate the role of those medications in pregnant women with 
MCTD, one can speculate that agents lowering the disease activity might have affected the 
pregnancy outcomes. Similarly, the use of LDA was seen to have a protective effect against 
adverse maternal and fetal outcomes as observed in other connective tissue diseases (e.g., 
SLE)[42]. A further important question is whether HCQ may play a role in preventing 
neonatal lupus and especially the recurrence of CHB in the foetus, as demonstrated in 
women with anti-Ro/SSA[43]. In both anti-U1RNP positive anti-Ro/SSA negative associated 
complete CHB cases the mother was not exposed to HCQ during pregnancy [5]. Further 
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studies are urgently required to address the potential role of HCQ in this setting of anti -
U1RNP.  
This study presents some limitations. First, its retrospective fashion. However, this aspect is 
counterbalanced by the facts that we report maternal and fetal findings from the largest 
ever-reported MCTD cohort, especially when taking into account the low prevalence of this 
condition in the general population. Secondly, treatments before and during pregnancy 
were based on the treating physician’s judgment. Thirdly, previous medical history of MCTD 
patients was heterogeneous, including different organs’ involvement and potentially 
affecting fetal outcome. In the same line, one could speculate if the current classification 
criteria for MCTD, heterogeneous and dated more than 30 years, are still the best tool to 
identify patients with this condition, in both research and clinical settings. Finally, one could 
wonder if the usual echocardiographic window (16-26 weeks) of screening for CHB in 
women with anti-SS-A might not be adequate in women with MCTD.  
 
In summary, acknowledging the limitations of retrospective data, our study suggests some 
important clinical messages: Firstly, women with MCTD should receive a specific counselling 
when planning a pregnancy. A suggested format could be similar to the pregnancy 
counselling  currently recommended for women with SLE and APS. Secondly, the observed 
live-birth-rate was 72%, with poorer fetal outcomes observed in MCTD women with aPL and 
pulmonary or muscular involvement. A closer pregnancy surveillance of these patients may 
therefore be considered. While the true frequency of heart block associated with anti-
U1RNP remains to be determined and prospective studies are highly needed to confirm our 
findings, our final clinical message is, that women with U1RNP antibodies should be offered 
echocardiographic surveillance during pregnancy to detect CHB in this setting.  
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Figure 1. Search strategy for the Systematic Review 
Table 1. Systematic review on cases of Neonatal Lupus born toanti-U1RNP antibodies positive 
patients 
Table 2. Demographic, clinical and laboratory characteristics of the cohort  
Table 3.Therapy undertaken by the patients before, during and after pregnancy. 
Table 4.PregnancyOutcomes 
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First Author 
Year of 
publication 
Number 
of 
cases 
Age of 
onset 
Heart 
Involvement  
Skin 
Involvement  
Type 
Systemic 
Involvement 
Maternal 
Diagnosis 
Provost et al. [19] 1987 2 
8 w ; 
Birth 
- 2 
Erythematous annular 
and targetoid lesions; 
Scaling and violaceous 
lesions, oral ulcers, 
follicular plugging, 
residual atrophic 
macules and 
teleangectasia 
- SLE; SLE 
Dugan et al. [9] 1992 2 3 w ; 4 w - 2 
Erythematous annular 
and polycyclic plaques, 
teleangectasia; 
Erythematous annular 
plaques, scale, residual 
hyperpigmentation 
Thrombocytosis MCTD; SLE 
Rider et al. [10] 1991 1 5 d - 1 
Edema, macular 
erythema 
Hypotonia SLE 
Lepore et al. [20] 1992 1 4 w - 1 
Erythematous papules, 
annular and reticulate 
erythema, residual 
atrophy 
Hepatomegaly  SLE 
Kaneko et al. [11] 1992 1 8 w   - 1 
Annular erythematous 
plaques 
- MCTD 
Sheth et al. [12] 1995 2 9 w ; 7 w - 2 
Annular scaly plaques, 
hypopigmentation; 
scaly erythematous 
patches, reticulate 
erythema 
- ; Thrombocytosis ND; MCTD 
Solomon et al. 
[13] 
1995 1 8 w - 1 
Scaly erythematous 
patches, scale, 
teleangectasia 
- SLE 
Cimaz et al. [14] 2002 1 Birth - 1 
Erythematous, atrophic 
lesions, scaling.  
- MCTD 
Fujiw aki et al. [15] 2003 1 3.5 w - 1 
Erythematous papules 
and subsequent discoid 
rash 
- MCTD 
McGeachy et al. 
[16] 
2009 1 Birth - 1 Scaly plaques - MCTD 
Penate et al. [17] 2009 1 1 w - 1 Scaly urticarial lesions 
Thrombocytopenia, 
anemia 
MCTD 
Acherman et al. 
[21] 
2010 1 
8 w  
gestation 
1, CHB 
(transient 1 
degree) 
- - - SLE 
Helaan et al. [18] 2013 1 Birth - 1 
Erythematous 
polycyclic scaly 
plaques, atrophy 
Thrombocytopenia MCTD 
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Izmirly et al. [6] 2017 1 Birth 1, CHB - - - MCTD 
Current Study 2018 2 Birth 1, CHB 1 
annular erythematous 
plaques with a slight 
scale 
- MCTD 
MCTD – Mixed connective tissue disease; SLE -  Systemic Lupus Erythematosus; CHB – cardiac heart block  
 
 
 
Table 1. Systematic review on cases of Neonatal Lupus born to anti -U1RNP antibodies positive patients  
“Pregnancy in mixed connective tissue disease” 
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Patients Characteristics All (94) % 
Age at conception, mean (S.D.), 
years 
28.9 (±6.3) 
 
Age at data collection, mean (S.D.), 
years 
45.1 (±10.9) 
 
Ethnicity 
  
Caucasians, n 64 68.1 
 
Blacks, n 9 9,6 
Asians, n 4 4,3 
Other, n 17 18 
Diagnosis   
MCTD 94 100 
Disease duration at data collection, 
mean (S.D.), years 
12.9(±8.5) 
 
MCTD and aPL 13 13.8 
 
MCTD and APS 6 6.4 
Clinical manifestations*   
Haematological, n 36 38.3 
Skin, n 57 60.6 
Joints, n 65 69.1 
Cardiac, n 10 10.6 
Renal, n 9 9.6 
Muscular, n 31 33 
Raynaud, n 66 70.2 
Pulmonary**, n 27 28.7 
Neurological, n 6 6.4 
Cardiovascular risk factors   
History of smoking, n 10 10.6 
Arterial Hypertension, n 13 13.8 
Hyperlipidemia, n 11 11.7 
Diabetes 2 2.1 
Laboratory testing   
Low C3 levels , n 28 29.8 
Low C4 levels , n 25 26.6 
anti-dsDNA positive, n 12 12.8 
anti-Ro/SSA and anti–La/SSB, n 4 4.3 
anti-Ro/SSA, n  22 23.4 
Hypergammaglobulinemia, n 47 50 
LA, n 14 14.9 
aCL (IgG/IgM), n  11 11.7 
anti-β2GPI(IgG/IgM), n 3 3.2 
 
 
29 
 
Table 2. Demographic, clinical and laboratory characteristics of the cohort  
“Pregnancy in mixed connective tissue disease” 
 
 
MCTD – Mixed connective tissue disease; aPL – Antiphospholipid Antibodies; APS – 
Antiphospholipid Syndrome; LA – lupus anticoagulant; aCL – anti-cardiolpin; anti-β2GPI – 
anti-βeta Glycoprotein I; Ig – Immunoglobulin  
*The listed Clinical manifestations of MCTD occurred at any time during disease course 
** Including Interstitial lung disease (42%), pulmonary fibrosis (33%) or pulmonary 
hypertension (25%) 
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Therapy Before pregnancy 
N(%*) 
During Pregnancy 
N(%*) 
After Pregnancy 
N(%*) 
Immunosuppressants    
Azathioprine  8 (3.9)  11 (5.42) 11 (5.42) 
Cyclosporine-A 2 (0.98) 2 (0.98) 0 
Mycophenolate 6 (3) 0 3 (1.48) 
Methotrexate 5 (2.46) 0 6 (2.96) 
Cyclophosphamide 7 (3.45) 0 0 
Rituximab 3 (1.48) 0 4 (1.97) 
Steroids 40 (19.7) 33 (16.26) 29 (14.29) 
Other    
Low Dose Aspirin 21 (10.34) 32 (15.76) 22 (10.84) 
Low molecular weight Heparin 2 (0.98) 15 (7.4) 12 (5.91) 
Vitamin K antagonists 2 (0.98) 0 1 (0.49) 
Hydroxychloroquine 40 (19.7) 37 (18.23) 38 (18.72) 
Statins 0 0 2 (0.98) 
Anti-hypertensive drugs 12 (5.91) 14 (6.9) 24 (11.82) 
Table 3.Therapy undertaken by the patients before, during and after pregnancy.  
“Pregnancy in mixed connective tissue disease” 
 
During pregnancy, 5 patients (2.46%) were taking both Azathioprine and Hydroxychloroquine, One patient was 
taking both Cyclosporine-A and Hydroxychloroquine (0.49%) and 16 were taking both Steroids and 
Hydroxychloroquine (7.88%). All patients with a previous diagnose of obstetric antiphospholipid syndrome 
received during pregnancy low dose aspirin, 3 out of 4 were also treated with low molecular weight heparin 
and one patient additionally received low dose steroids.  
 
*rates are calculated based on the number of pregnancies as: x/203*100 
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Pregnancy Characteristics All (203) % 
Age at conception, mean (S.D.) 28,9 (±6.3)  
Mode of delivery   
Vaginal, n  97 67.8* 
Vaginal Spontaneous/induced, % 88/12  
Cesarean section, n 50 34.2* 
Outcomes   
Live births 147 72.4 
Miscarriages 38 18.7 
Stillbirths 18 8.9 
Weight at Birth, mean (S.D.), grams 2930.2 (± 917.6)  
Gestation Duration, mean (S.D.), weeks 35.2 (± 7.5)  
Complications   
IUGR 11 5.4 
Pre-eclampsia 8 3.9 
Eclampsia 2 0.9 
Gestational Hypertension 31 15.3 
Gestational Diabetes 3 1.5 
Other Neonatal and Obstetric Complications   
Respiratory Distress 3 1.5 
Septicemia** 1 0.5 
Premature Rupture of the Membranes 1 0.5 
Absent end-diastolic flow velocity on umbilical artery 1 0.5 
Oligohydramnios 2 1 
Placental Abruption 2 1 
Table 4. Pregnancy Outcomes 
“Pregnancy in mixed connective tissue disease” 
 
IUGR – Intrauterine growth restriction;  
*Percentages are calculated considering viable babies (total=147)  
** the episode of Septicemia resulted in death  
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